Document Detail

Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.
MedLine Citation:
PMID:  6758569     Owner:  NLM     Status:  MEDLINE    
Thirty patients with refractory advanced breast cancer who had no prior treatment with doxorubicin or VP-16-213 received doxorubicin 45 mg/m2 I.V. on day 1 and VP-16-213 50 mg/m2 I.V. on days 1 through 5. Courses were repeated every 21 days when hematologic recovery permitted. Among 30 evaluable patients, one had a complete response and 11 had a partial response. Four patients had stabilization of their disease. There was thus a 40% response rate with a median response duration of 146 days (range 35-540). Toxicity included moderate to severe myelosuppression, infections, hemorrhage, and mucositis. In these poor prognoses in previously treated patients, the combination of doxorubicin and VP-16-213 appears to be an effective secondary treatment for metastatic breast cancer.
P H Konits; D A Van Echo; J Aisner; D Morris; P H Wiernik
Related Documents :
11036959 - Use of docetaxel (taxotere) in patients with paclitaxel (taxol) hypersensitivity.
25431259 - The clinical utility of microrna-21 as novel biomarker for diagnosing human cancers.
1721719 - Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination wit...
7740329 - Docetaxel (taxotere) in the treatment of solid tumors other than breast and lung cancer.
10482189 - Current management of metastatic breast cancer.
11273589 - North central cancer treatment group--mayo clinic trials in colon cancer.
9519169 - How do palliative physicians manage venous thromboembolism?
14610409 - Determinants of prostate cancer specific survival following radiation therapy during th...
20001209 - The nf-kappab activation pathways, emerging molecular targets for cancer prevention and...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  American journal of clinical oncology     Volume:  5     ISSN:  0277-3732     ISO Abbreviation:  Am. J. Clin. Oncol.     Publication Date:  1982 Oct 
Date Detail:
Created Date:  1983-02-14     Completed Date:  1983-02-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  515-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / drug therapy*
Clinical Trials as Topic
Doxorubicin / administration & dosage*,  adverse effects
Drug Therapy, Combination
Etoposide / administration & dosage*,  adverse effects
Infusions, Parenteral
Leukopenia / chemically induced
Middle Aged
Podophyllotoxin / analogs & derivatives*
Thrombocytopenia / chemically induced
Reg. No./Substance:
23214-92-8/Doxorubicin; 33419-42-0/Etoposide; 518-28-5/Podophyllotoxin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stimulation of prostacyclin production from vascular endothelial cells by plasma, serum and platelet...
Next Document:  Colitis caused by Clostridium difficile: a review.